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Abstract
In this multicenter, phase II, single-arm study, 52 patients with recurrent or metastatic HER2-positive (D)
breast cancer received ﬁrst-line eribulin with trastuzumab. The objective response rate (ORR) was 71.2%
(n[ 37) with a median time to ﬁrst response (TTR) of 1.3 months; duration of response (DOR) and progression-
free survival (PFS) were 11.1 and 11.6 months, respectively. Eribulin/trastuzumab combination resulted in a
substantial tumor response with an acceptable safety proﬁle.
Background: The aim of this study was to assess efﬁcacy and safety of eribulin with trastuzumab as ﬁrst-line therapy
for locally recurrent or metastatic HER2þ breast cancer. Patients and Methods: In this multicenter, phase II, single-
arm study, patients with recurrent or metastatic HER2þ breast cancer received eribulin mesylate at 1.4 mg/m2
intravenously (I.V.) on days 1 and 8 of each 21-day cycle with an initial trastuzumab dose of 8 mg/kg I.V. on day 1,
followed by 6 mg/kg of trastuzumab on day 1 of each subsequent cycle. Tumor assessments were conducted every
6 weeks for the ﬁrst 6 cycles and every 12 weeks thereafter. The primary end point was ORR, and secondary end
points included PFS, TTR, DOR, and safety. Results: Fifty-two patients were enrolled. Fifty-one patients (98.1%) had
metastatic disease, 25 (48.1%) with liver metastases, 24 (46.2%) with lung metastases, and 19 (36.5%) with bone
metastases. Patients received a median of 10.0 cycles of eribulin and 11.0 cycles of trastuzumab. The ORR was
71.2% (n ¼ 37) with median TTR of 1.3 months, DOR of 11.1 months, and PFS of 11.6 months. The most common
Grade 3/4 treatment-emergent adverse events were neutropenia in 20 (38.5%) patients, peripheral neuropathy in 14
(26.9%; all Grade 3) patients, fatigue in 4 (7.7%) patients, and febrile neutropenia in 4 (7.7%) patients. Conclusions:
Because of the high ORR, prolonged median PFS, and acceptable safety proﬁle, combination eribulin/trastuzumab is
an acceptable treatment option for locally recurrent or metastatic HER2þ breast cancer.
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406 -breast cancer with tumors positive for the transmembrane tyrosine
kinase receptor was 22.2% (range, 9%-74%).3 In addition, the
frequency of HER2-positivity is increased among patients with
metastatic disease.4
Trastuzumab, a humanized monoclonal antibody directed against
the extracellular domain of HER2,5 combined with recently approved
pertuzumab, is recommended as part of ﬁrst-line therapy for women
with HER2-positive (þ) tumors and metastatic disease.6 Results from
multiple clinical trials have demonstrated that the combination of
trastuzumab and pertuzumab with any of several conventional
chemotherapeutic agents, including carboplatin, docetaxel, vinor-
elbine, paclitaxel, or capecitabine, is effective for the treatment of
HER2-overexpressing metastatic breast cancer (MBC).7-17
Eribulin mesylate is a nontaxane inhibitor of microtubule dy-
namics in the halichondrin class of antineoplastic drugs.18-21 Spe-
ciﬁcally, eribulin is a microtubule inhibitor that is a structurally
modiﬁed synthetic analogue of halichondrin B.18 Eribulin has a
novel mode of action that is distinct from those of other tubulin-
targeting agents; it only binds to the growing positive ends, inhib-
iting the microtubule growth phase without affecting the shortening
phase and causing tubulin sequestration into nonproductive aggre-
gates.18-21 This unique tubulin-based mechanism of action might
explain how eribulin is able to overcome taxane resistance and have
potentially a wider clinical effect.22
Approval of eribulin in the United States, European Union,
Japan, and other countries was based on the Eisai Metastatic Breast
Cancer Study Assessing Physician’s Choice Versus E7389
(EMBRACE), a phase III open-label study in which women with
locally recurrent or metastatic breast cancer were randomly allocated
(2:1) to eribulin mesylate or treatment of physician’s choice.23 The
phase III EMBRACE study showed signiﬁcant improvements in
overall survival with eribulin versus treating physician’s choice of
therapy (most often including vinorelbine, gemcitabine, or capeci-
tabine) in previously treated women with MBC. Results from
EMBRACE also indicated that the safety and tolerability of eribulin
were similar to those for the other chemotherapeutic agents used in
the study, and that rates of peripheral neuropathy for eribulin and
taxanes were 35% and 45%, respectively. In addition, the authors of
the EMBRACE study noted that eribulin has a short infusion time
and requires no premedication to prevent hypersensitivity.23
Because of its antitumor activity in the challenging setting of late-
line treatment, infusion time (1.4 mg/m2 intravenous [I.V.] over 2-
5 minutes on days 1 and 8 of a 21-day cycle), and no premedication
requirement to prevent hypersensitivity, assessment of eribulin in
the ﬁrst-line setting for women with MBC is warranted.23,24 The
objective of this phase II trial was to assess the antitumor activity
and safety of eribulin in combination with trastuzumab as ﬁrst-line
therapy for patients with locally recurrent or metastatic HER2þ
breast cancer.
Patients and Methods
Study Design
In this multicenter, single-arm, phase II trial, we assessed the
objective response rate (ORR) of eribulin in combination with
trastuzumab in patients with locally recurrent (regardless of
resectability) or metastatic HER2þ breast cancer. The study had
3 phases: screening and baseline, six 21-day cycles of eribulin withClinical Breast Cancer December 2014trastuzumab, and an extension phase in which patients who
completed the initial 6 cycles continued to receive study treatment
until the development of progressive disease (PD) or until another
withdrawal criterion was met.
The study was conducted in accordance with the Declaration of
Helsinki (2008), and the protocol and informed consent forms were
submitted for approval to institutional review boards by the primary
investigators. All patients provided written informed consent before
undergoing any study-related procedures.
Patients
Women  18 years of age were eligible for inclusion if they met
the following criteria: histologically or cytologically proven recurrent
or metastatic adenocarcinoma of the breast with at least 1 measur-
able lesion according to Response Evaluation Criteria in Solid Tu-
mors (RECIST) 1.1; a HER2þ tumor determined by a score of 3þ
on immunohistochemistry staining or gene ampliﬁcation by ﬂuo-
rescence in situ hybridization; life expectancy of  24 weeks;
Eastern Cooperative Oncology Group (ECOG) performance status
of 0, 1, or 2;  12 months since previous neoadjuvant or adjuvant
chemotherapy (no washout period for previous adjuvant
trastuzumab);  2 weeks since previous radiotherapy or endocrine
therapy, trastuzumab, or lapatinib, with complete recovery from the
effects of these interventions; and adequate renal, bone marrow,
liver, and cardiac function. Previous hormonal therapy was allowed.
Patients were excluded if they had received previous chemo-
therapy, biologic therapy, or investigational therapy for locally
recurrent or metastatic HER2þ breast cancer; had previous
exposure of > 360 mg/m2 of doxorubicin or > 720 mg/m2 of
epirubicin; preexisting Grade 3 or 4 neuropathy; or clinically sig-
niﬁcant cardiovascular impairment (history of congestive heart
failure greater than New York Heart Association [NYHA] Class II;
unstable/active angina or myocardial infarction  6 months before
day 1, or serious cardiac arrhythmia).
Treatment
Patients received 6 cycles of eribulin mesylate 1.4 mg/m2
administered I.V. with infusion over 2 to 5 minutes on days 1 and 8
of each 21-day cycle and trastuzumab 8 mg/kg I.V. over 90 minutes
on day 1 of cycle 1. Thereafter, trastuzumab 6 mg/kg was infused
over 30 minutes on day 1 of each subsequent 21-day cycle. Dose
reductions for eribulin, but not for trastuzumab, were permitted.
Two dose reductions (1.1, 0.7 mg/kg) were allowed before
consideration of study treatment discontinuation. Eribulin could be
continued as monotherapy if trastuzumab was discontinued, and
vice-versa.
Concomitant Medications
Any medication that was considered necessary for the patient’s
welfare and was not expected to interfere with the evaluation of
study treatment could be given at the discretion of the inves-
tigator. This included granulocyte colony-stimulating factor,
granulocyte-macrophage colony-stimulating factor, and erythro-
poietin, administered according to American Society of Clinical
Oncology guidelines and standard practice; stable bisphosphonate
doses; and palliative radiotherapy (< 10% of bone marrow).
Other antitumor therapies were not permitted.
Table 1 Demographic and Clinical Characteristics of Study
Patients
Category
Eribulin/Trastuzumab
(n [ 52)
Median Age, Years (Range) 59.5 (31-81)
Race, n (%)
White 40 (76.9)
Black or African American 11 (21.2)
Asian 1 (1.9)
Ethnicity, n (%)
Hispanic or Latino 5 (9.6)
Not Hispanic or Latino 47 (90.4)
ECOG Performance Status, n (%)
0 37 (71.2)
1 14 (26.9)
2 1 (1.9)
Mean Time From Original Diagnosis
of Breast Cancer, Years (SD)
3.0 (3.3)
Mean Age at Diagnosis, Years (SD) 56.3 (11.6)
Breast Cancer Stage, n (%)
IIB 0
IIIA 51 (98.1)
IIIB 0
IV 0
NA 1 (1.9)
Metastatic Breast Cancer, n (%)a 51 (98.1)
Metastases, n (%)
Liver 25 (48.1)
Lung 24 (46.2)
Brain 1 (1.9)
Bone 19 (36.5)
Skin 3 (5.8)
Other 33 (63.5)
Organs Involved, n (%)
1 15 (28.8)
2 24 (46.2)
3 13 (25.0)
Previous Anticancer Therapy, n (%)
Taxane or anthracycline 25 (48.1)
Trastuzumab or lapatinib 22 (42.3)
Abbreviation: ECOG ¼ Eastern Cooperative Oncology Group.
aFifty-one of 52 patients had metastatic disease at baseline.
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Baseline tumor assessments (computed tomography or magnetic
resonance imaging scans) of the chest, abdomen, pelvis, and other
areas of known disease were performed within 28 days before the
ﬁrst infusion of study treatment, every 6 weeks during the treatment
phase, and every 12 weeks in the extension phase. The primary end
point was antitumor activity of eribulin with trastuzumab assessed
by determining ORR-based investigator review using RECIST 1.1.
The ORR was deﬁned as the proportion of subjects who achieved a
complete response (CR) plus those who achieved a partial response
(PR). To be assigned a status of PR or CR, changes in tumor
measurements must have been conﬁrmed in repeat evaluations
carried out  4 weeks after the response criteria were ﬁrst met.
Secondary end points included time to ﬁrst response (TTR) and
duration of response (DOR) for patients whose best overall response
was CR or PR and progression-free survival (PFS). Quality of life
(QoL) was assessed using the European Organisation for Research
and Treatment of Cancer QoL assessment tool (QLQ-C30) and
breast module BR23 at screening or baseline, every other cycle
during the study, and end-of-treatment visit; results are forthcoming
and will be presented in a future analysis.
Safety and Tolerability
Safety parameters included adverse events (AEs) and serious AEs
(SAEs); hematology and clinical chemistry; physical examinations;
periodic measurement of vital signs and electrocardiograms
(ECGs); and evaluation of left ventricular ejection fraction (LVEF)
using multigated acquisition scans or echocardiograms and were
assessed at baseline, every fourth treatment cycle, and at the end-
of-treatment visit. AEs had to occur after and not before dosing
of study treatment. All AEs were followed until resolution or for
30 days after the subject’s last study visit. However, treatment-
emergent peripheral neuropathy and alopecia of any grade were
followed until resolution or until another anticancer therapy was
started. AEs were graded on a 5-point scale according to National
Cancer Institute Common Terminology Criteria for Adverse
Events version 4.0.
Statistical Analysis
All efﬁcacy analyses were based primarily on the full analysis set,
which included all patients who received  1 dose of study treat-
ment. Baseline demographic and clinical characteristics were sum-
marized. The ORR was determined along with corresponding
2-sided, exact binomial 95% conﬁdence intervals (CIs). TTR,
DOR, and PFS were analyzed using Kaplan-Meier product-limit
estimates. Disease control rate (DCR; CR þ PR þ stable disease),
clinical beneﬁt rate (CBR; CR þ PR þ stable disease  6 months),
and 95% CIs were also determined. For PFS subgroup analysis,
95% CIs were calculated; because of the small sample size, no
covariate adjustment was made in the analysis.
Results
Patient Characteristics
A total of 52 patients (median age of 59.5 years), 51 (98.1%)
with metastatic disease, entered the study; 45 patients completed
the treatment phase (the ﬁrst 6 cycles of treatment) and 9 dis-
continued because of AEs (n ¼ 3), PD (n ¼ 3), or other reasons(n ¼ 3; Table 1). Eight patients were still in the extension phase of
the treatment at the time of clinical data cut. Median daily intensity
was 0.13 mg/m2/d (minimum, 0.1; maximum, 1.4) per patient.
Mean number of eribulin doses was 23.8 and the median number of
cycles received per patient was 10.0 (range, 0-38) for eribulin and
11.0 (range, 1-37) for trastuzumab. No patient received palliative
radiotherapy during the study.
Efﬁcacy
Overall, 52 patients in the full analysis set were evaluable
for ORR (Table 2). The ORR was 71.2% (n ¼ 37; 95% CI,Clinical Breast Cancer December 2014 - 407
Table 2 Tumor Responses
Response Category, n (%)
Eribulin/Trastuzumab
(n [ 52)
Objective Response Rate; 95% CI 37 (71.2); 56.9-82.9
Complete Response 3 (5.8)
Partial Response 34 (65.4)
Stable Disease 13 (25.0)
Progressive Disease 1 (1.9)
Not Evaluable 1 (1.9)
Clinical Beneﬁt Rate; 95% CIa 44 (84.6); 71.9-93.1
Disease Control Rate; 95% CIb 50 (96.2); 86.8-99.5
aClinical beneﬁt rate ¼ CR þ PR þ stable disease ( 6 months).
bDisease control rate ¼ CR þ PR þ stable disease.
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408 -56.9-82.9), the DCR was 96.2% (n ¼ 50; 95% CI, 86.8-99.5), and
the CBR was 84.6% (n ¼ 44; 95% CI, 71.9-93.1). Investigator
assessments indicated CR in 3 (5.8%) patients and PR in 34
(65.4%) patients. The median TTR for patients with CR or PR was
1.3 months (95% CI, 1.2-1.4). The median DOR was 11.1 months
(95% CI, 6.7-17.8). A summary of percent changes in the total sum
of target lesion diameters is shown in Figure 1. The median percent
change from baseline was 62.4%. In patients who received a dose
reduction (n ¼ 21), tumor response rates were greater compared
with those who did not (n ¼ 31) in ORR (17 [81.0%] vs. 20
[64.5%]), DCR (21 [100.0%] vs. 29 [93.5%]), CBR (20 [95.2%]
vs. 24 [77.4%]), and durable stable disease (3 [14.3%] vs. 4
[12.9%]).
The median PFS was 11.6 months (95% CI, 9.1-13.9; Figure 2)
and Kaplan-Meier estimates for the 3-, 6-, 9-, and 12-month PFS
rates were 96%, 82%, 67%, and 49%, respectively. Forest plot of
PFS subgroup analyses are included in Figure 3. Factors associated
with a shorter PFS (> 2-month reduction in PFS vs. the overall
median value) were patients with hormone-negative disease
(9.5 months; n ¼ 15); estrogen receptor-positive/progesteroneFigure 1 Waterfall Graph of Percentage Change in Total Sum of Ta
(RECIST 1.1)
-100
-80
-60
-40
-20
0
20
40
S
1 4 7 10 13 16 19 22
Pe
rc
en
ta
ge
 C
ha
ng
e 
Fr
om
 B
as
el
in
e
Abbreviation: RECIST ¼ Response Evaluation Criteria in Solid Tumors.
Clinical Breast Cancer December 2014receptor-positive (9.2 months; n ¼ 21); baseline ECOG status 1 or
2 (9.2 months; n ¼ 15); < 2 years from adjuvant or neoadjuvant
therapy to start of current treatment (5.0 months; n ¼ 6); MBC
diagnosed within 3 months of original diagnosis (9.5 months; n ¼
20); liver involvement (9.5 months; n ¼ 25); and metastases
involving 2 organs (9.2 months; n ¼ 24). PFS was extended by >
2 months versus the overall median value in metastases involving
the number of target lesions (> 3) (13.9 months; n ¼ 6); however,
these subgroups are small, and therefore results should be inter-
preted with caution.
Safety
All patients reported treatment-emergent AEs (TEAEs), and all
reported TEAEs that were considered to be related to either eri-
bulin or trastuzumab (Table 3). Grade  3 TEAEs according to
the Common Terminology Criteria for Adverse Events (CTCAE)
were reported by 37 (71.2%) patients and SAEs were reported
by 15 (28.8%) of patients.
The most common TEAEs (all grades occurring in  50% of
patients) were alopecia (88.5%; n ¼ 46), fatigue (69.2%; n ¼ 36),
neutropenia (59.6%; n ¼ 31), and peripheral neuropathy (69.2%; n
¼ 36; as classiﬁed from the Standardized Medical Dictionary for
Regulatory Activities Queries [SMQ], which includes all forms of
neuropathy combined). The most common Grade 3/4 TEAEs
(occurring in  5% of patients) were neutropenia (38.5%; n ¼ 20),
peripheral neuropathy (26.9%; n ¼ 14 [SMQ]), fatigue (7.7%; n ¼
4), febrile neutropenia (7.7%; n ¼ 4), leukopenia (5.8%; n ¼ 3),
vomiting (5.8%; n ¼ 3), and hyperglycemia (5.8%; n ¼ 3). Of
these, Grade 4 TEAEs were seen for neutropenia and febrile neu-
tropenia. The median time to onset for all peripheral neuropathy
was 113 days (95% CI, 69.0-155.0; n ¼ 36) after the initiation of
treatment; for Grade 3/4 peripheral neuropathy, median time to
onset was 568 days (95% CI, 400.0-not estimable; n ¼ 14). The
median duration was 155 days (95% CI, 78.0-351.0; n ¼ 36) for
peripheral neuropathy and 23 days (95% CI, 8.0-56.0; n ¼ 14) for
Grade 3/4 peripheral neuropathy resolving to Grade 1/2.rget Lesion Diameters From Baseline to Post-Baseline Nadir
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Sharon Wilks et alTreatment-emergent AEs led to dose adjustment (interruption/
delay, reduction, or discontinuation/withdrawal) of either eribulin,
trastuzumab, or both, in 36 (69.2%) patients. Speciﬁcally, TEAEs
led to withdrawal of 1 or both study drugs in 11 (21.2%) patients,
dose reduction in 21 (40.4%) patients, and study drug interruptionFigure 3 Forest Plot of Subgroup Analyses
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a For all patients in the full analysis set.
b For full analysis set patients with previous adjuvant or neoadjuvant therapies.in 22 (42.3%) patients. Peripheral neuropathy led to discontinuations
in 7 (13.5%) patients, dose reduction in 10 (19.2%) patients, and
dose interruption in 5 (9.6%) patients. Neutropenia led to dose
reductions in 6 (11.5%) patients and dose interruptions in 11
(21.2%) patients, but it did not lead to any discontinuations.
Serious TEAEs occurred in 15 patients (28.8%). Neutropenia
(all Grades) occurred in 8 (15.4%) patients, febrile neutropenia
(all Grades) in 4 (7.7%), peripheral neuropathy (SMQ term) in
4 (7.7%), and vomiting in 3 (5.8%). There was 1 death during
the study. A 59-year-old white patient died from chronic heart
failure 15 days after her last dose of study treatment, after a total
treatment duration of 274 days. At baseline, the patient was
receiving amlodipine, furosemide, atorvastin, losartan, and ateno-
lol, and medications for diabetes. Medical and surgical history
included arteriosclerosis of the coronary artery, coronary artery
bypass, diabetes mellitus, hyperlipidemia, and hypertension. The
patient had NYHA Class I, ECOG was 0, and her LVEF values at
baseline were normal. Her LVEF evaluations at screening, baseline,
and cycle 12, day 1 were 71%, 71%, and 55%, respectively. The
patient did not meet the criteria for exclusion which were clinically
signiﬁcant cardiovascular impairment (ie, history of congestive
heart failure greater than NYHA Class II, unstable/active angina or
myocardial infarction  6 months before day 1 of this study, or13.5 (6.70-15.15)
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Table 3 Treatment-Emergent Adverse Events (All Grades
in > 10% of Patients, or Grades 3/4/5 in > 5% of
Patients)
TEAE
All Grades
(n [ 52)
Grades 3/4/5
(n [ 52)
Alopecia 46 (88.5) NA
Fatigue 36 (69.2) 4 (7.7)
Peripheral Neuropathya 36 (69.2) 14 (26.9)
Neutropenia 31 (59.6) 20 (38.5)
Nausea 24 (46.2) 2 (3.8)
Diarrhea 17 (32.7) 2 (3.8)
Anemia 13 (25.0) 1 (1.9)
Constipation 13 (25.0) 0
Decreased Appetite 13 (25.0) 0
Dysgeusia 12 (23.1) 0
Edema, Peripheral 12 (23.1) 0
Pyrexia 12 (23.1) 1 (1.9)
Vomiting 12 (23.1) 3 (5.8)
Dyspepsia 10 (19.2) 2 (3.8)
Headache 10 (19.2) 2 (3.8)
Leukopenia 9 (17.3) 3 (5.8)
Stomatitis 9 (17.3) 0
Dizziness 8 (15.4) 0
Back Pain 8 (15.4) 0
Chills 8 (15.4) 1 (1.9)
Lacrimation Increased 8 (15.4) 0
Bone Pain 7 (13.5) 0
Dyspnea 7 (13.5) 1 (1.9)
Insomnia 7 (13.5) 0
Muscle Spasms 7 (13.5) 0
Oropharyngeal Pain 7 (13.5) 0
Urinary Tract Infection 7 (13.5) 1 (1.9)
Abdominal Pain 6 (11.5) 0
Depression 6 (11.5) 0
Weight Decreased 6 (11.5) 0
Febrile Neutropenia 4 (7.7) 4 (7.7)
Hyperglycemia 3 (5.8) 3 (5.8)
Data are presented as n (%).
Abbreviation: NA ¼ not applicable; TEAE ¼ treatment-emergent adverse event.
aPeripheral neuropathy includes the following preferred terms: neuropathy peripheral,
neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensory neuropathy,
peripheral sensorimotor neuropathy, demyelinating polyneuropathy, and paresthesia.
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410 -serious cardiac arrhythmia). The death was considered to be
possibly related to the study drug by the treating investigator.
Grade 3/4 clinical laboratory hematologic abnormalities included
leukocytes (23.1%; n ¼ 12), neutrophils (55.8%; n ¼ 29), and
lymphocytes (2.2%; n ¼ 1). Grade 3/4 clinical chemistry abnor-
malities included increases in alanine aminotransferase (2.0%;
n ¼ 1), sodium (3.8%; n ¼ 2), potassium (3.8%; n ¼ 2), phos-
phorus (4.0%; n ¼ 2), and calcium (1.9%; n ¼ 1).
One subject (1.9%)with normal baseline ECGand3 subjects (5.8%)
with clinically nonsigniﬁcant abnormal ECG ﬁndings at baseline had
clinically signiﬁcant abnormal ﬁndings during the study. The median
change from baseline to end of treatment for LVEF was 5.0%. The
3 patients with Grade 2 LVEF decrease had trastuzumab dose delay.Clinical Breast Cancer December 2014Discussion
The results of this phase II trial suggest the combination of eri-
bulin with trastuzumab has considerable activity with an acceptable
toxicity proﬁle as ﬁrst-line therapy for HER2þ locally advanced or
metastatic breast cancer. Results for the 52 patients evaluated in this
phase II, single-arm study indicated ORR in 37 (71.2%) patients.
The median DOR was 11.1 months and the median PFS was 11.6
months. The most common Grade 3/4 TEAEs (occurring in  5%
of patients) were neutropenia (38.5%; n ¼ 20), peripheral neu-
ropathy (26.9%; n ¼ 14, all Grade 3 [SMQ]), fatigue (7.7%;
n ¼ 4), febrile neutropenia (7.7%; n ¼ 4), vomiting (5.8%; n ¼ 3),
leucopenia (5.8%; n ¼ 3), and hyperglycemia (5.8%; n ¼ 3).
Guidelines currently recommend pertuzumab with trastuzumab
in combination with a taxane as a preferred option for ﬁrst-line
treatment of patients with HER2þ MBC.6 Other ﬁrst-line treat-
ment regimens for HER2þ tumors include HER2þ blockading
treatments such as trastuzumab with chemotherapy.6 The activity
demonstrated for eribulin with trastuzumab as ﬁrst-line treatment
for women with HER2þ locally advanced or metastatic breast
cancer in the present study appears comparable with that reported
for other chemotherapy combinations evaluated in this setting.
Along with lapatinib, 4 chemotherapeutic agents are currently
recommended in combination with trastuzumab as ﬁrst-line
treatment for patients with HER2þ MBC: docetaxel, vinor-
elbine, capecitabine, and paclitaxel with or without carboplatin.6
Results for trastuzumab with docetaxel have indicated PFS
ranging from 8.3 to 12.4 months and ORR ranging from 45% to
64%.25-28 Results for vinorelbine with trastuzumab are generally
similar to those that have been reported for docetaxel. One study
that compared vinorelbine combined with trastuzumab and
docetaxel combined with trastuzumab reported PFS of 15.3 and
12.4 months, respectively, and an ORR of 59.3% in both arms.27
A second study that combined oral or I.V. vinorelbine with tras-
tuzumab reported PFS of 9.3 months and an ORR of 70.3%.7 The
combination of trastuzumab and capecitabine has been shown to
result in PFS of 7.8 to 9.3 months and an ORR of 38% to 65% in
patients with HER2þ MBC.10,29 Results for the combination of
trastuzumab and paclitaxel indicated PFS ranging from 7.1 to
12.3 months and ORR of 36% to 75%.30-32 A PFS of 10.7
months and an ORR of 52% have been reported for the combi-
nation of trastuzumab with paclitaxel and carboplatin.32
The activity of eribulin with trastuzumab appears comparable with
that of other combinations currently recommended for HER2þ
MBC. Although incidence rates vary, peripheral neuropathy is a
common AE in patients treated with microtubule-targeted agents
occurring in up to 30% of patients.33 Peripheral neuropathy Grade
3/4 also occurs frequently in patients treated with eribulin. In the
phase 3 EMBRACE trial, 35% of eribulin-treated patients had
neuropathy, but < 9% had Grade 3/4 neuropathy.23 In the present
study, 36 (69.2%) patients experienced neuropathy, and 14 (26.9%)
experienced Grade 3 neuropathy; no Grade 4 neuropathy was
observed. This higher rate of Grade 3 neuropathy was likely due to
the prolonged duration of eribulin treatment in this ﬁrst-line setting.
In phase II and III trials in which patients with HER2þ MBC
received microtubule-targeting agents as ﬁrst-line treatment, rates of
Grade 3/4 febrile neutropenia ranged from 10.1% to 37.4%.25-28
Sharon Wilks et alHigh rates of Grade 3/4 neutropenia were often reported particularly
in combination trials of docetaxel and trastuzumab. Across several
trials, rates ofGrade 3/4 neutropenia ranged from32.0% to 61.1%.25-
28 With other treatment combinations in similar patient populations,
high rates of Grade 3/4 neutropenia also occurred: Andersson et al
reported 41.5% in patients receiving vinorelbine and trastuzumab
and in a phase III trial,27 Robert et al reported 27% of patients
receiving trastuzumab and paclitaxel and 57% receiving carboplatin
with trastuzumab and paclitaxel reportedGrade 3/4 neutropenia.32 In
the current trial, all Grades of febrile neutropenia and neutropenia
occurred in 4 (7.7%) and 31 (59.6%) patients and Grade 3/4 was
reported in 4 (7.7%) and 20 (38.5%) patients, respectively.
The duration of treatment (patients received 10.0 cycles [median]
of eribulin treatment) could have contributed to cumulative
neuropathic toxicity; notably, the median time to onset of
treatment-emergent Grade 3/4 peripheral neuropathy was 568 days
and the median duration of treatment-emergent peripheral neu-
ropathy was 155 days for any Grade and 23 days for Grade 3/4.
Although dose reductions were caused mostly by neutropenia and
peripheral neuropathy, patients who received a modiﬁed dose ach-
ieved greater tumor response rates (ie, ORR, DCR, CBR, and
durable stable disease) compared with those who did not. Thus,
patients continued to derive clinical beneﬁt from eribulin regardless
of whether dose was reduced or maintained.
A recent systematic review of clinical studies of patients with
MBC indicated that Grade 3/4 peripheral sensory neuropathy
might occur in as many as 30.9% of patients treated with docetaxel
and 33% of those treated with paclitaxel.34 Analysis of phase II/III
studies of ixabepilone in patients with pretreated MBC indicated
that Grade 3/4 peripheral sensory neuropathy might occur in
approximately 20% of patients.35 The suggested clinical differences
between eribulin and other microtubule-targeted agents are con-
sistent with results from an experimental animal study that indi-
cated eribulin had no effects on caudal and digital nerve conduction
velocity and amplitude, compared with signiﬁcant reductions in
both of these measures with paclitaxel and ixabepilone. Eribulin
caused mild changes in the structure of the sciatic nerve and dorsal
root ganglion cells, compared with moderate-to-severe degenerative
changes for paclitaxel and ixabepilone.36
Neuropathic symptoms resulting from treatment can cause
treatment delays, dose reductions, or even discontinuation of ther-
apy, and reduced QoL, and might interfere with activities of daily
living, all of which can affect outcomes and compromise survival.37
Although rigorous studies on the assessment, prevention, and
management of cancer treatment-related neuropathy are limited,
guidelines suggest that physicians actively query cancer patients on
signs and symptoms of neuropathy, especially considering that un-
derestimation and underreporting of symptoms is common.37 Patient
history should include associated comorbidity, including inquiring
about diabetes history or history of sensory neuropathy, personal and
family history of neuropathy, alcohol use and other toxic exposures,
and any neuropathy experienced during previous treatment.37 A
detailed treatment proﬁle should be described (regimen dosage,
duration, schedule, coasting), and the characteristics and distribution
of signs and symptoms.37 Recommended physician-based grading
systems include the National Cancer Institute CTCAE,38 Ajani
Sensory,39 World Health Organization,40 and ECOG systems.41Because neuropathy often progresses with dose accumulation,
early reporting of mild cases is important when detecting the onset
of neuropathy during continuous monitoring.37 To that end,
guidelines recommend using the following pain assessment tools to
assess neuropathic symptoms: Brief Pain Inventory,42,43 Neuro-
pathic Pain Scale,44,45 and Leeds Assessment of Neuropathic
Symptoms and Signs Pain Scale,46,47 for the identiﬁcation and
assessment of functional deﬁcits associated with neuropathy.37
Conclusion
In this multicenter, phase II, single-arm study, the efﬁcacy and
safety of eribulin with trastuzumab as ﬁrst-line therapy for HER2þ
MBC were assessed in 52 patients and showed an ORR of 71.2%
(n ¼ 37), DOR of 11.1 months, and a median PFS of 11.6 months.
The most common Grade 3/4 TEAEs (occurring in  5% of pa-
tients) were neutropenia (38.5%; n ¼ 20), peripheral neuropathy
(21.2%, n ¼ 11; all Grade 3), fatigue (7.7%; n ¼ 4), febrile neu-
tropenia (7.7%; n ¼ 4), vomiting (5.8%; n ¼ 3), leucopenia (5.8%;
n ¼ 3), and hyperglycemia (5.8%; n ¼ 3).
The combination of eribulin with trastuzumab as ﬁrst-line
therapy for HER2þ MBC resulted in higher objective response
and CBRs, and a prolonged median PFS with an acceptable safety
proﬁle similar to other single agents that have been commonly
combined with trastuzumab as ﬁrst-line therapy. Combined eribulin
and trastuzumab is an acceptable treatment option for patients with
HER2þ MBC.
Clinical Practice Points
 The prognosis for patients with MBC at initial diagnosis is poor,
with an estimated 5-year survival rate of 24.3%.1
 Approximately 22% (range, 9%-74%) of patients with breast
cancer have tumors that are positive for HER2,3 and the fre-
quency of HER2-positivity is increased among patients with
metastatic disease.4
 The EMBRACE study demonstrated improved survival and
acceptable tolerability after eribulin treatment for advanced
breast cancer in patients with at least 2 previous therapies.23
 Eribulin has a short infusion time and requires no premedication
to prevent hypersensitivity.23
 Assessment of eribulin in the ﬁrst-line setting for women with
MBC was warranted, because of its ease of use and its antitumor
activity in the challenging setting of late-line treatment.
 The objective of this phase 2 trial was to assess the antitumor
activity and safety of eribulin in combination with trastuzumab
as ﬁrst-line therapy for patients with locally recurrent or meta-
static HER2þ breast cancer.
 Results for the 52 patients evaluated in this phase II, single-
arm study indicated ORR in 71.2%. The median DOR was
11.1 months and the median PFS was 11.6 months. The most
common Grade 3/4 TEAEs (occurring in  5% of patients)
were neutropenia (38.5%), peripheral neuropathy (21.2%, all
Grade 3), fatigue (7.7%), febrile neutropenia (7.7%), vomiting
(5.8%), hyperglycemia (5.8%), and leucopenia (5.8%).
 The results presented here suggest the combination of eribulin
with trastuzumab has considerable activity with an acceptable
toxicity proﬁle as ﬁrst-line therapy for HER2þ locally advanced
or metastatic breast cancer.Clinical Breast Cancer December 2014 - 411
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